|
|
News Breaks | | | | September 7, 2012 | | 08:31 EDT |  | CYTR | CytRx's Aldoxorubicin data selected for presentation
CytRx Corporation announced that favorable results from a Phase 1b/2 clinical trial with aldoxorubicin in patients with advanced soft tissue sarcoma will be featured in a poster and discussion presentation at the Connective Tissue Oncology Society 17th Annual Meeting on November 15 in Prague, Czech Republic. The Phase 1b/2 clinical trial results, first announced in early June 2012 at the American Society of Clinical Oncology conference, showed clinical benefit with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with advanced, metastatic soft tissue sarcomas who had either not responded or relapsed after receiving one to three prior chemotherapies. Eight of the 13 patients had been treated previously with doxorubicin. | |
|
News For CYTR From The Last 14 Days Check below for free stories on CYTR the last two weeks. |
|
|
| May 20, 2013 | | 08:37 EDT | | CYTR | CytRx expects data from three aldoxorubicin trials this year
 Subscribe for More Information | | | May 9, 2013 | | 08:39 EDT |  | CYTR | CytRx reports Q1 EPS (23c), consensus (15c)
Subscribe for More Information | | | May 8, 2013 | | 08:35 EDT | | CYTR | CytRx to focus on clinical development of aldoxorubicin
Subscribe for More Information | | | May 6, 2013 | | 08:33 EDT | | CYTR | CytRx receives recommendation from DSMC to complete Phase 2b trial
Subscribe for More Information | |
|
|
|
|
|
|
